RNA editing signatures identify melanoma patients who respond to Pembrolizumab or Nivolumab treatment

Immunotherapy has improved the prognosis for many melanoma patients; however, our capacity to predict patient responses and to understand the biological differences between patients who will or will not respond is limited. Gene expression profiling of tumors from patients who respond to immunotherap...

Full description

Bibliographic Details
Main Authors: Jalal Siddiqui, Wayne O. Miles
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523321001893